Progressive decreases in platelet-bound fibrinogen accessibility to antibody and enzymes were recently reported t o occur after adenosine diphosphate (ADP)-induced fibrinogen binding. Because previous studies also indicated that platelets that are activated but not aggregated by ADP in the presence of fibrinogen lose their ability t o aggregate in a timedependent manner despite negligible changes in fibrinogen binding, the present study examined the relationship between platelet aggregation and accessibility of plateletbound fibrinogen t o specific polyclonal antibody F(ab'), fragments over a 60-minute time course. Although '%fibrinogen binding remained virtually unchanged, comparison of antifibrinogen antibody F(ab'), binding and platelet aggregation 5 minutes and 60 minutes after platelet stimulation with ADP or thrombin showed decreases in F(ab'), binding of 62% f 13% and 73% f 7% (mean 2 SD, n = 5). respectively, and decreases of 65% f 16% and 60% f 10% in platelet aggregation. In contrast, platelets stimulated with A23187 or chymotrypsin retained 87% 2 16% and 76% f 12% of their
I quence of platelet stimulation by a wide variety of agonists.' These include small molecules such as adenosine diphosphate (ADP) and epinephrine, proteases such as thrombin and chymotrypsin, large molecules such as collagen, and various calcium ionophores. Whereas it is certain that platelet stimulation is a prerequisite for fibrinogen binding, the mechanism of fibrinogen receptor induction is incompletely understood. A variety of intracellular mediators have been implicated including G-proteins, protein kinase C activation, IP,, and calcium mobilization.' Although the number of fibrinogen receptors exposed after platelet stimulation varies with agonist concentration and type,' fibrinogen binding characteristics are similar. Binding occurs predominantly to the platelet membrane glycoprotein (GP) IIb-IIIa complex,' is divalent cation dependent,' and can be inhibited by synthetic peptides mimicking the a-chain Arg-Gly-Asp (RGD) sequence or the y-chain pentadecapeptide sequence of fibrin~gen.~.~ Fibrinogen binding is a prerequisite for platelet aggregation.' Although fibrinogen binding is necessary, several studies suggest that it may not be sufficient for aggregation.'.' For example, platelets that are activated but not aggregated by ADP in the presence of fibrinogen lose their ability to aggregate over the same time course, and lost only 39% f 14% and 36% 2 12% of their ability t o bind antifibrinogen antibody F(ab'), fragments, respectively. Pretreatment of ADP-stimulated platelets with chymotrypsin largely prevented the progressive loss of platelet aggregability and the accompanying decreased recognition of bound fibrinogen by antifibrinogen F(ab'), fragments. Preincubation of platelets with cytochalasin D (30 pg/mL) also inhibited the decrease in platelet aggregation after exposure of ADP-treated platelets t o fibrinogen over a 60-minute time course. This was accompanied by only a 25% 2 18% decrease in antifibrinogen antibody F(ab'), binding. Present data support the hypothesis that qualitative changes in platelet-bound fibrinogen correlate with loss of the ability of platelets t o aggregate, and implicate both the platelet cytoskeleton and chymotrypsin-sensitive surface membrane structures in modulating qualitative changes in bound fibrinogen on the platelet surface.
o 1992 by The American Society of Hematology. ability to aggregate in a time-dependent manner, despite negligible changes in fibrinogen binding.s This dissociation between fibrinogen binding and platelet aggregation, and recent observations of progressive decreases in plateletassociated fibrinogen accessibility to antibody with time after equilibrium fibrinogen binding, suggest the hypothesis that qualitative changes in surface membrane-bound fibrinogen after platelet stimulation may correlate with the ability of activated platelets to aggregate. This hypothesis is consistent with reports by Lindon et al; who showed a direct relationship between platelet adhesion to fibrinogencoated surfaces and antifibrinogen antibody binding to deposited fibrinogen. Thus, the present study was designed to evaluate the potential correlation between the ability of ADP-, thrombin-, A23187-, or chymotrypsin-treated platelets to aggregate and changes in bound fibrinogen recognition by antifibrinogen F(ab')' fragments at various times after platelet exposure to fibrinogen.
MATERIALS AND METHODS
Blood was obtained from volunteers after receiving informed consent. Samples were collected into 0.1 vol 3.2% sodium citrate and 0.05 yo1 1 mmol/L aspirin. Platelet-rich plasma (PRP) was prepared by centrifugation (2SOg for 15 minutes). Platelets were separated from plasma by gel-filtration over Sepharose 2B (Pharmacia, Piscataway, NJ) equilibrated with 0.01 mol/L HEPES-buffered, modified Tyrode's solution (HBMT), pH 7.5, containing no added calcium, 2 mmol/L magnesium, 2 mg/mL bovine serum albumin (fatty acid free; Sigma Chemical Co, St Louis, MO), and 1 mg/mL dextrose, as previously described.' Platelet suspensions contained 250,000 to 300,000 plateletsikL.
Prostaglandin E, (PGE,) treated and formalin-fixed platelets were prepared as follows. Unstimulated, gel-filtered platelets were incubated with 0.1 kmol/L PGE, (Sigma; 30 minutes at 22°C) or an equal volume of 2% formalin (60 minutes at 22°C). Samples were washed twice by centrifugation (1,OOOg for 20 minutes) and resuspension in 0.15 moliL NaCl containing 5 mmol/L EDTA. Washed, PGE,-treated or formalin-fixed platelets were finally resuspended in HBMT. Fibrinogen preparation. Band I fibrinogen was purified from fresh-frozen plasma as previously described? It was radiolabeled with "'iodine and an immobilized oxidant (N-chlorobenzenesulfonamide:iodobeads; Pierce Chemical Co, Rockford, IL) according to the instructions provided by the manufacturer. Protein-bound and free iodine were separated by gel-filtration over Sephadex G-25 (Pharmacia) equilibrated with 0.15 mol/L NaCI.
Platelet preparation.
Antifibrinogen antibodies. Affinity-purified, antifibrinogen IgG from rabbits (Accurate Chemical and Scientific Co, Westbury NY) was digested with pepsin to produce F(ab')z fragments." Fc fragments were absorbed on protein A using a 10% cell suspension of Staphylococcus aureus (Sigma). F(ab'), fragments were labeled with "'iodine using iodobeads (Pierce) as described for fibrinogen above.
Platelets were stimulated with a variety of agonists. ADP (10 pmol/L) or A23187 (5 pmol/L) were added to platelet suspensions in the presence of either '"I-labeled (10 pg/mL) or unlabeled fibrinogen (10 pg/mL, 100 pg/mL). Additional platelet samples were stimulated with 150 mU/mL human thrombin (a kind gift from Dr J Fenton, NY State Department of Health, Albany, NY). Thrombin was neutralized with a 10-fold excess of hirudin 5 minutes after platelet stimulation, and before addition of fibrinogen. Other platelet samples were exposed to chymotrypsin (200 p,g/mL; Worthington, Freehold, NJ) for 15 minutes at 37°C. Chymotrypsin was neutralized with a 10-fold molar excess of phenylmethylsulfonyl fluoride (PMSF). EDTA (5 mmol/L) was added to the platelet suspension, and the preparation was centrifuged (15 minutes at 1,000g at 22°C). The resulting platelet pellet was resuspended in HBMT, followed immediately by the addition of fibrinogen. In some experiments, chymotqpsintreated platelets were also stimulated with 10 pmol/L ADP before adding fibrinogen. Stimulated platelets were incubated for up to 60 minutes (22°C) in the presence of fibrinogen without agitation to prevent aggregation. No macroscopic aggregates were noted over this time course.
Chymotrypsin-treated platelets were also evaluated for GPIb degradation and GPIIIa digestion. GPIb degradation was assessed using the 6D1 monoclonal antibody (MoAb) (a gift from Dr B. Coller, SUNY, at Stony Brook)." GPIIIa digestion was assessed using a monoclonal anti-GPIIIa antibody (SZ 21; AMAC, Inc, Westbrook, ME) on Western blots of lysed chymotrypsin-treated platelets."
In other experiments, platelets were preincubated (30 minutes at 22°C) with 30 pg/mL cytochalasin D (Sigma) before stimulation. Platelets incubated with dimethyl sulfoxide (DMSO) served as controls. Activation-induced cytoskeleton formation was assessed based on the ability of platelets to retract reptilase-induced (Bothrops atrox serine proteinase; Abbot Laboratories, N. Chicago, IL) fibrin clots at 37T, as described previously." The extent of clot retraction (percentage) was calculated based on the amount of fluid expressed from the clot relative to the starting volume of the platelet/fibrinogen suspension.
Stimulated platelets were incubated with '251-fibrinogen (10 pg/mL) at 22"Cwithout stirring. lZI-fibrinogen binding was assessed after 5 minutes and 60 minutes by centrifugation of duplicate sample aliquots through silicone oil. Platelet-associated radioactivity was quantified in a gamma counter (MicroMedic Systems 4/600; Rohm and Haas Co, Horsham, PA). Nonspecific IzI-fibrinogen binding was assessed in the presence of 10 mmol/L EDTA or 5 mg/mL unlabeled fibrinogen.'
In parallel experiments, stimulated platelets were incubated (22°C) in the presence of 10 pg/mL unlabeled fibrinogen. After 5 minutes and 60 minutes, '"I-antifibrinogen F(ab'), fragments (50 pg/mL) were added. F(ab'), binding was assessed after a subse-Platelet stimulation.
Fibrinogen and antifibrinogen F(ab'), binding.
quent 30 minutes of incubation (22"C), when equilibrium F(ab'), binding had 0cc~rred.I~ Nonspecific F(ab')z binding was quantified using stimulated platelets that were incubated with fibrinogen in the presence of 10 mmol/L EDTA to prevent specific plateletfibrinogen interactions?
Platelet aggregation. The ability of platelets to aggregate was evaluated in parallel with their ability to bind antifibrinogen antibody F(ab'), fragments. Separate suspensions of stimulated platelets were incubated (22°C) with 0.1 mg/mL unlabeled fibrinogen. Sample agitation was minimal to prevent aggregation during the incubation period. After 5 minutes and 60 minutes, 0.5 mL aliquots were removed and aggregated in a dual channel aggregometer with the temperature set to 37°C (Chronolog Corp, Haverton, PA). Instrument baselines were adjusted to 90% light transmission using a buffer blank, and 10% light transmission using unstimulated platelets. The extent of platelet aggregation was quantified and used as an indicator of platelet function.
RESULTS
A comparison of fibrinogen and antifibrinogen antibody F(ab'>* binding to platelets after exposure to 10 pg/mL exogenous fibrinogen for 5 minutes and 60 minutes is presented in Fig 1. Platelets were stimulated with ADP, thrombin, chymotrypsin, or A23187. As reported previ-o~s l y , '~ antifibrinogen F(ab'), fragment binding to ADPtreated platelets declined markedly during the 60 minutes of incubation, despite little change in overall fibrinogen binding. Similar observations were made with thrombinstimulated platelets. In contrast, platelets stimulated with A23187 or chymotrypsin retained significantly more of their ability to bind antifibrinogen F(ab'), fragments over the same time course (P < .OS).
Parallel studies showed that decreases in antifibrinogen antibody F(ab')2 fragment binding to ADP-and thrombintreated platelets correlated with decreases in platelet aggregation ( Fig 1) . Moreover, platelets stimulated with A23187 or chymotrypsin retained most of their ability to aggregate 60 minutes after exposure to 0.1 mg/mL fibrinogen (Figs 1 and 2A), consistent with the smaller, observed decreases in antifibrinogen antibody F(ab'), binding. When equal parts of fresh, chymotrypsin-treated platelets were combined with ADP-treated platelets that had been incubated with fibrinogen for 60 minutes, the platelet mixture aggregated less well than chymotrypsin-treated platelets alone or chymotrypsin-treated platelets combined with ADP-treated platelets that had been incubated with fibrinogen for 5 minutes (Table 1) . Indeed, ADP-treated platelets incubated with fibrinogen for 60 minutes behaved similarly to PGE,-treated platelets or unstimulated, formalin-ked plate- Chymo-treated + formalin-fixed7 -2 4 f 18 *Incubation time reflects the length of time ADP-treated platelets were exposed to fibrinogen (0.1 mg/mL) before aggregation was initiated.
tAggregation was induced by stirring samples at 37°C in an aggregometer. The extent of platelet aggregation is expressed relative to that of fresh, chymotrypsin-treated platelets. Values represent mean 2 SD, n = 3.
*Chymotrypsin-treated platelets were aggregated at 37°C in the presence of 0.1 mg/mL fibrinogen by stirring in an aggregometer.
§ADP-treated platelets were aggregated by stirring in an aggregometer either 5 minutes or 60 minutes after exposure to fibrinogen (0.1 mg/mL).
(Platelet mixtures consisted of equal parts of fresh, chymotrypsintreated platelets combined with ADP-or PGE,-treated platelets, or unstimulated, formalin-fixed platelets. Platelets were stimulated with 10 pmol/L ADP, 0.2 mglmL chymotrypsin, or chymotrypsin followed by ADP, as described in Materials and Methods.
Table 2. Pretreatment of ADP-Stimulated Platelets With Chymotrypsin: Effect on Platelet Aggregation and Antifibrinogen Antibody F(ab'), Fragment Binding 60 Minutes Compared With 5 Minutes After Platelet Exposure to Fibrinogen
*Antifibrinogen antibody F(ab'), binding, 60 minutes after exposure of stimulated platelets to 0.01 mg/mL fibrinogen at 22°C. is expressed relative to binding noted at 5 minutes. Values represent mean 2 SD, n = 5.
tPlateiet aggregation 60 minutes after exposure of stimulated platelets to 0.1 mglmL fibrinogen is expressed relative to platelet aggregation at 5 minutes. Values represent mean f SD, n = 5.
* §Differences between paired samples were not statistically significant (P > .2), as determined using the Student's t-test.
lets in aggregation studies with chymotrypsin-treated platelets ( Table 1) . Table 3 , Table 3 Platelets were incubated with increasing doses of chymotrypsin for 15 minutes at 37°C. Chymotrypsin was neutralized with PMSF and platelets washed, resuspended in HBMT, and stimulated with 10 Fmol/L ADP. All values represent the mean f SD of three separate experiments.
Decreases in antifibrinogen F(ab'), binding and platelet aggregation accompanying the exposure of ADP-stimulated platelets to fibrinogen for 60 minutes could be prevented by pretreating platelets with chymotrypsin (Table 2). A s GPIb and GPIIIa degradation result from chymotrypsin t~eatment,'~.'~ studies were performed to examine the relationship between chymotrypsin-induced GPIb and GPIIIa digestion and modulation of antifibrinogen antibody F(ab'), binding. As summarized in

. Effect of Chymotrypsin-Induced GPlb and GPilla Digestion and Modulation of Antifibrinogen Antibody F(ab'), Binding to Platelets After Subsequent Stimulation with ADP
*Degradation of GPlb was quantified using the 6D1 MoAb." 6D1 binding to chymotrypsin-treated platelets is expressed as a percentage relative to 6D1 binding to untreated, control platelets.
tDegradation of GPllla to its 66-Kd fragment was assessed on Western blots of lysed chymotrypsin-treated platelets using a commercial anti-GPllla MoAb.', The data represent the amount of the 66-Kd fragment seen as a percentage relative to total platelet GPllla.
SAntifibrinogen antibody F(ab'), binding reflects binding to stimulated platelets 60 minutes compared with 5 minutes after exposure to 10 Fg/mLfibrinogen. Binding at 5 minutes was taken as 100%.
For personal use only. on November 15, 2017. by guest www.bloodjournal.org From RECOGNITION OF PLATELET-ASSOCIATED FIBRINOGEN 2031 platelets exposed to increasing concentrations of chymotrypsin showed an increased loss of surface GPIb, inferred from decreased binding of the 6D1 monoclonal anti-GPIb antibody." In addition, chymotrypsin treatment was accompanied by the appearance of a 66-Kd GPIIIa fragment, as assessed by immunoblotting of lysed chymotrypsin-treated platelets. No correlation between GPIb degradation or the appearance of the 66-Kd GPIIIa fragment and changes in antifibrinogen antibody F(ab')2 binding emerged, however.
Additional studies were performed to assess the role of actin polymerization in modulating fibrinogen expression on the platelet surface. Compared with control platelets treated with DMSO, platelets preincubated with cytochalasin D retained more of their ability to aggregate (Fig 2B) and showed significantly (P < .02) smaller decreases in antifibrinogen antibody F( ab')* binding 60 minutes as compared with 5 minutes after stimulation with ADP (Fig  3) . Time-dependent changes in the ability of cytochalasintreated platelets to aggregate after stimulation with ADP and exposure to fibrinogen were modest compared with those demonstrated by DMSO-treated samples. Indeed, the largest decrease in cytochalasin-treated platelet aggregation over a 60-minute time course is shown in Fig 2B. In comparison, DMSO-treated, control platelets lost twice as much of their ability to aggregate in parallel studies. As reported previou~ly,'~ cytochalasin D-treated platelets bound less fibrinogen and aggregated less well than their DMSOtreated counterparts. The data presented in Fig 3, therefore, reflect changes in fibrinogen binding, antifibrinogen antibody F(ab'), binding, and platelet aggregation relative to control values (T = 5 minutes) for each treatment group.
DISCUSSION
Platelet aggregation is the result of a sequence of reactions that occur largely at the surface membrane and include agonist binding, signal transduction, modification of GPIIb-IIIa, and fibrinogen binding.* Although a strong correlation exists between platelet aggregation and fibrinogen binding,' discrepancies between platelet-fibrinogen interactions and platelet aggregation have been de-s~r i b e d .~.~ For example, it is well known that platelets lose their ability to aggregate if they are exposed to agonist in the presence of fibrinogen before platelet-platelet interactions are initiated by stirring or otherwise agitating the sample." Previous characterization of such platelets showed no decreases in fibrinogen binding? Results from the present study suggest that qualitative, not quantitative, changes in bound fibrinogen are likely to contribute to the observed decrease in platelet aggregation. Indeed, the present study provides evidence for a strong correlation between time-dependent decreases in fibrinogen accessibility to antibody and platelet aggregability. Platelets stimulated with ADP or thrombin gradually lost their ability to aggregate, and exhibited substantial decreases in antifibrinogen antibody F(ab'), binding within 60 minutes after exposure to fibrinogen. In contrast, platelets stimulated with A23187 or chymotrypsin showed a significantly smaller decrease in antifibrinogen antibody F(ab'), binding over the same time course, and retained more of their ability to aggregate.
The data further show that ADP-treated platelets fail not only to interact with each other after 60 minutes of incubation with fibrinogen at 22"C, but also with freshly stimulated, chymotrypsin-treated platelets. Aggregation responses recorded for mixtures of chymotrypsin-treated platelets and ADP-treated platelets exposed to fibrinogen for 60 minutes resembled those obtained with combinations of chymotrypsin-treated platelets and PGE,-treated platelets or unstimulated, formalin-ked platelets. These findings suggest that ADP-treated platelets, incubated with fibrinogen for 60 minutes, are as inert in terms of aggregating with fresh chymotrypsin-treated platelets as unstimulated platelets. If platelet aggregation is the result of fibrinogen binding to receptors on adjacent platelets, these observations may further suggest that fibrinogen bound to stimulated platelets for 60 minutes has lost its ability to combine with available receptors on neighboring platelets.
Progressive, qualitative changes in bound fibrinogen and platelet aggregation associated with exposure of ADPtreated platelets to fibrinogen over a 60-minute time course could be prevented by the pretreatment of platelets with chymotrypsin. These data support the hypothesis that chymotrypsin-sensitive surface membrane structures participate in the observed modulation of fibrinogen expression on ADP-treated platelets. No correlation between chymotrypsin-induced degradation of GPIbI5 or digestion of GPIIIa to its 66-Kd fragmenP and loss of platelet aggregability or changes in platelet-associated fibrinogen accessibility to antibody could be demonstrated, however. Proteolytic events preceeding the appearance of the 66-Kd GPIIIa fragment," degradation of GPIIb, and/or proteolysis of the GPIIb-IIIa microenvironment may play potential roles in the modulation of fibrinogen expression on stimulated platelets. The observation that pretreatment of platelets with as little as 10 pg/mL chymotrypsin was sufficient to prevent ADPinduced qualitative changes in fibrinogen binding suggests For personal use only. on November 15, 2017. by guest www.bloodjournal.org From that the membrane protein(s) apparently contributing to this process is/are highly susceptible to proteolysis.
Further studies implicate actin polymerization in the modulation of fibrinogen expression on ADP-treated platelets and platelet aggregation. Platelets pretreated with cytochalasin D retained much of their ability to aggregate after 60 minutes of exposure to fibrinogen. Moreover, platelet-associated fibrinogen remained largely accessible to antifibrinogen F(ab')z fragments. This apparent correlation between cytoskeleton activation and observed, qualitative changes in bound fibrinogen on the surface of ADPtreated platelets may also explain the relative lack of such changes after platelet stimulation with chymotrypsin or A23187. Chymotrypsin has been shown to expose fibrinogen receptors via proteolysis rather than intracellular signal transduction, as evidenced by the lack of effect of metabolic inhibitors and PGE, treatment on fibrinogen binding and platelet aggregation." The lack of cytoskeleton activation by these platelets has been inferred from studies demonstrating an inability of chymotrypsin-treated platelets to retract fibrin In comparison, platelet stimulation with A23187 is accompanied by activation of intracellular calpains and degradation of cytoskeletal proteins, including actin-binding protein, which plays a role in actin filament organization.*' Indeed, degradation of actinbinding protein was a consistent finding after platelet stimulation with A23187 in the present studies (data not shown).
The association between time-dependent, qualitative changes in bound fibrinogen on the platelet surface and platelet cytoskeleton activation may suggest bound fibrinogen redistribution, or internalization. Cytoskeleton-dependent events such as receptor clustering? sequestration of bound fibrinogen in channels of the surface canalicular system,23 and fibrinogen internalization have been de-~c r i b e d .~~,~~ Internalization is unlikely under present experimental conditions, as bound fibrinogen remains accessible to proteolysis by plasmin or ~hymotrypsin.'~ Fibrinogen sequestration in areas of the open canalicular system, which may not be readily accessible to antibody and partially accessible to proteases, however, may relate to present observations.
Recently, Gralnick et aiB also reported qualitative changes in bound fibrinogen on thrombin-stimulated platelets using an MoAb recognizing an epitope in the fibrinogen D domain. These investigators showed decreases in whole antibody and F(ab')2 binding to platelets over a 60-minute time course, but no significant changes in Fab fragment binding, consistent with stearic constraints limiting antibody access to platelet-associated fibrinogen. Interestingly, studies with polyclonal antibodiesI4 showed similar timedependent decreases for both antifibrinogen IgG and Fab fragment binding to platelets, thus raising the possibility that certain epitopes on fibrinogen may remain relatively more accessible to specific MoAb Fab fragments after fibrinogen binding to stimulated platelets.
Additional studies are required to elucidate the mechanism(s) responsible for the apparent qualitative changes in bound fibrinogen on stimulated platelets. The present study demonstrates an agonist specific modulation that is dependent on cytoskeleton activation and is sensitive to proteolysis by chymotrypsin. The data further provide a correlation between qualitative changes in bound fibrinogen on the surface of stimulated platelets and the ability of platelets to aggregate. Interestingly, other adhesive proteins, fibronectin and von Willebrand factor: when bound to thrombintreated platelets, remain largely unchanged as assessed recently using polyclonal antibodies." These findings may have implications for the regulation of hemostasis and thrombosis. For example, qualitative changes in bound fibrinogen on ADPor thrombin-treated platelets could provide a protective mechanism whereby the exposure of platelet-associated fibrinogen that does not participate in platelet-platelet contacts is modified to limit thrombus formation.
